Immune Modulating Effects and Safety of Vvax001, a Therapeutic Semliki Forest Virus Based Cancer Vaccine, in Patients With a History of (Pre) Malignant Cervical Lesions.
Phase of Trial: Phase I
Latest Information Update: 09 May 2018
At a glance
- Drugs Vvax 001 (Primary)
- Indications Cervical cancer
- Focus Pharmacodynamics
- 02 May 2018 Status changed from recruiting to completed.
- 08 May 2017 New trial record